Physician profile
Daniel E Ross
NPI 1528037256
$27,103.48
in general payments reported to CMS, 2019-2025
82 companies · $4,327 in 2025
The $4,327 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,975 · 2020: $2,222 · 2021: $3,289 · 2022: $4,085 · 2023: $4,434 · 2024: $5,772 · 2025: $4,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,224.70 |
| Education | $308.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,503.64 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Jazz Pharmaceuticals INC. | $1,783.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,443.96 | 2019-2025 | |
| Pfizer INC. | $1,438.96 | 2021-2025 | |
| Mdd US Operations, LLC | $1,290.17 | 2019-2025 | Gocovri |
| Sk Life Science, INC. | $1,105.53 | 2020-2025 | Xcopri |
| Biogen, INC. | $1,097.51 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $942.29 | 2019-2025 | Nayzilam, Briviact, Zilbrysq |
| Lundbeck LLC | $851.06 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $795.30 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $790.53 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $782.29 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $714.83 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $596.00 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $495.14 | 2020-2025 | Firdapse, Fycompa |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.